Side effects were generally dose-dependent starting on a lower dose and gradually increasing may help reduce gastrointestinal discomfort
ISO 659
These actions can lead to good weight reduction, especially when used with lifestyle changes
Insurance coverage decisions typically require demonstration of obesity through BMI thresholds with or without metabolic comorbidities but do not specifically require established cardiovascular disease
Many offer discounts to make the medications more affordable
Of these, 1,956 gastrointestinal reports were for exenatide (9.19%), 2,891 for liraglutide (13.58%), 10,757 for dulaglutide (50.55%), 182 for lixisenatide (0.86%), and 5,567 (26.16%) for semaglutide ( Figure 1 )